SLC5A2 and heart failure: It is also worthy of note that a meta-analysis of patients treated with SGLT-2 inhibitors indicates the benefit of this class of drugs in reducing hospitalization due to heart failure [107], which was also a conclusion of the analysis by Masson et al., (2021) [105].